LGC said the acquisition will improve its position across the clinical quality control tools market and increase its proficiency testing offerings.
CoPrimers use a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker, which prevents the formation of primer-dimers.
The deal marks the latest in a series of acquisition LGC has made in recent years to expand its presence on the nucleic acid chemistry market.
London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.
LGC will offer NuGen's single-primer enrichment technology for next-generation sequencing target enrichment.
LGC will supply DNA fragmentation instruments for clinical and agricultural biotechnology customers.
The company will integrate the oligonucleotide manufacturer with two of its existing sections to form a new Nucleic Acid Chemistry business unit.
Backed by €15 million in EU funding, the Ubiquitous Pharmacogenomics Consortium seeks to implement preemptive testing at seven healthcare systems by 2020.
The partners will evaluate several quality control assays for genome editing research, eventually creating a protocol for analyzing mutations in genomic DNA.
The UK-based firm plans to marry its core strengths with the probes and PCR platforms, and to build its sales force in the US.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.